Epitel raised $26 million in a Series B to expand market access for its wireless EEG seizure monitoring system. The Remi remote EEG platform is built for home monitoring, enabling continuous tracking of seizures while patients continue day-to-day activities. Epitel said Remi integrates with its Remi Vigilenz AI system, which uses machine learning to identify and log seizure events. The funding will support expansion of access and commercialization. This financing reflects continued investor appetite for connected neurodiagnostics that shift monitoring from clinic-centered workflows to at-home care models.